News from isis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 18, 2015, 09:30 ET
Ionis Pharmaceuticals

Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc.  Ionis...

Dec 17, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating...

Dec 11, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx...

Nov 10, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.8 million milestone payment from Biogen related to the...

Nov 09, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Reports Financial Results and Highlights for Third Quarter 2015

 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported consolidated financial results for the third quarter of 2015 and highlighted...

Nov 08, 2015, 10:30 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and its subsidiary, Akcea Therapeutics, today announced positive results from a Phase 2 study of...

Nov 06, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

Nov 05, 2015, 07:00 ET
Akcea Therapeutics

Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and its wholly owned subsidiary, Akcea Therapeutics, today announced the start of a Phase 3 study to...

Nov 04, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at American Heart Association Scientific Sessions

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Sunday, November 8 at 1:00 p.m. Eastern Time to...

Nov 03, 2015, 06:00 ET
LA60006LOGO

Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented Today at the EC-ATTR Meeting

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive preliminary results from an ongoing investigator sponsored, open-label...

Oct 30, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal...

Oct 27, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, November 3 at 8:00 a.m. Eastern Time to...

Oct 26, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

ISIS Pharmaceuticals Earns $5 Million from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the initiation...

Oct 23, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Isis Pharmaceuticals' Third Quarter 2015 Financial Results Conference Call

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, November 9 at 11:30 a.m. Eastern Time to...

Oct 15, 2015, 19:33 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated an open-label extension study, SHINE.  The SHINE study...

Sep 11, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its collaboration with AstraZeneca to discover and develop antisense drugs for...

Sep 03, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

Aug 04, 2015, 09:00 ET
Isis Pharmaceuticals, Inc.

Isis Reports Financial Results And Highlights For Second Quarter 2015

 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported net income of $35.6 million and $18.9 million for the three and six months ended June...

Aug 03, 2015, 17:00 ET
Isis Pharmaceuticals, Inc.

Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia

Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the FOCUS FH phase 3 study of KYNAMRO® (mipomersen sodium) in patients with...

Aug 03, 2015, 02:00 ET
Isis Pharmaceuticals, Inc.

AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense...